vs
Princeton Bancorp, Inc.（BPRN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Princeton Bancorp, Inc.的1.5倍（$30.3M vs $20.7M），Princeton Bancorp, Inc.净利率更高（29.3% vs -221.3%，领先250.6%），REGENXBIO Inc.同比增速更快（43.0% vs 3.6%），Princeton Bancorp, Inc.自由现金流更多（$20.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 9.1%）
普林斯顿银行控股公司是一家总部位于美国的银行控股企业，通过旗下社区银行子公司开展业务，提供零售与商业银行全品类服务，包括存款账户、中小企业贷款、个人消费贷款、抵押贷款及财富管理服务，主要服务新泽西州及美国中大西洋地区客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BPRN vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.7M
营收增速更快
RGNX
高出39.4%
3.6%
净利率更高
BPRN
高出250.6%
-221.3%
自由现金流更多
BPRN
多$73.4M
$-52.8M
两年增速更快
RGNX
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.7M | $30.3M |
| 净利润 | $6.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 38.2% | -190.0% |
| 净利率 | 29.3% | -221.3% |
| 营收同比 | 3.6% | 43.0% |
| 净利润同比 | 16.3% | -31.2% |
| 每股收益（稀释后） | $0.89 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BPRNRGNX
| Q4 25 | $20.7M | $30.3M | ||
| Q3 25 | $21.5M | $29.7M | ||
| Q2 25 | $21.1M | $21.4M | ||
| Q1 25 | $20.9M | $89.0M | ||
| Q4 24 | $20.0M | $21.2M | ||
| Q3 24 | $19.2M | $24.2M | ||
| Q2 24 | $18.1M | $22.3M | ||
| Q1 24 | $17.4M | $15.6M |
净利润BPRNRGNX
| Q4 25 | $6.1M | $-67.1M | ||
| Q3 25 | $6.5M | $-61.9M | ||
| Q2 25 | $688.0K | $-70.9M | ||
| Q1 25 | $5.4M | $6.1M | ||
| Q4 24 | $5.2M | $-51.2M | ||
| Q3 24 | $-4.5M | $-59.6M | ||
| Q2 24 | $5.1M | $-53.0M | ||
| Q1 24 | $4.3M | $-63.3M |
毛利率BPRNRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BPRNRGNX
| Q4 25 | 38.2% | -190.0% | ||
| Q3 25 | 38.5% | -176.3% | ||
| Q2 25 | 2.8% | -296.3% | ||
| Q1 25 | 32.9% | 13.6% | ||
| Q4 24 | 34.0% | -242.1% | ||
| Q3 24 | -29.1% | -256.6% | ||
| Q2 24 | 34.1% | -251.3% | ||
| Q1 24 | 31.0% | -408.8% |
净利率BPRNRGNX
| Q4 25 | 29.3% | -221.3% | ||
| Q3 25 | 30.0% | -208.3% | ||
| Q2 25 | 3.3% | -331.8% | ||
| Q1 25 | 25.7% | 6.8% | ||
| Q4 24 | 26.1% | -241.3% | ||
| Q3 24 | -23.3% | -246.3% | ||
| Q2 24 | 28.4% | -237.7% | ||
| Q1 24 | 24.9% | -405.4% |
每股收益（稀释后）BPRNRGNX
| Q4 25 | $0.89 | $-1.30 | ||
| Q3 25 | $0.95 | $-1.20 | ||
| Q2 25 | $0.10 | $-1.38 | ||
| Q1 25 | $0.77 | $0.12 | ||
| Q4 24 | $0.75 | $-0.99 | ||
| Q3 24 | $-0.68 | $-1.17 | ||
| Q2 24 | $0.80 | $-1.05 | ||
| Q1 24 | $0.68 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $270.7M | $102.7M |
| 总资产 | $2.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BPRNRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务BPRNRGNX
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $10.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BPRNRGNX
| Q4 25 | $270.7M | $102.7M | ||
| Q3 25 | $266.6M | $161.5M | ||
| Q2 25 | $261.9M | $213.7M | ||
| Q1 25 | $267.0M | $274.2M | ||
| Q4 24 | $262.0M | $259.7M | ||
| Q3 24 | $261.5M | $301.4M | ||
| Q2 24 | $244.8M | $348.3M | ||
| Q1 24 | $241.8M | $390.7M |
总资产BPRNRGNX
| Q4 25 | $2.3B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | $2.2B | $581.0M | ||
| Q1 25 | $2.3B | $490.9M | ||
| Q4 24 | $2.3B | $466.0M | ||
| Q3 24 | $2.4B | $519.1M | ||
| Q2 24 | $2.0B | $569.4M | ||
| Q1 24 | $2.0B | $629.2M |
负债/权益比BPRNRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $20.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | 99.3% | -174.0% |
| 资本支出强度资本支出/营收 | 4.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.54× | — |
| 过去12个月自由现金流最近4个季度 | $29.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BPRNRGNX
| Q4 25 | $21.5M | $-52.3M | ||
| Q3 25 | $4.9M | $-56.0M | ||
| Q2 25 | $3.1M | $-49.3M | ||
| Q1 25 | $1.3M | $33.6M | ||
| Q4 24 | $14.7M | $-31.6M | ||
| Q3 24 | $1.2M | $-40.5M | ||
| Q2 24 | $4.3M | $-45.5M | ||
| Q1 24 | $4.8M | $-55.5M |
自由现金流BPRNRGNX
| Q4 25 | $20.6M | $-52.8M | ||
| Q3 25 | $4.7M | $-56.5M | ||
| Q2 25 | $2.9M | $-49.7M | ||
| Q1 25 | $1.1M | $32.6M | ||
| Q4 24 | $13.2M | $-32.7M | ||
| Q3 24 | $766.0K | $-40.9M | ||
| Q2 24 | $3.9M | $-46.0M | ||
| Q1 24 | $4.8M | $-56.0M |
自由现金流率BPRNRGNX
| Q4 25 | 99.3% | -174.0% | ||
| Q3 25 | 21.6% | -189.9% | ||
| Q2 25 | 13.7% | -232.8% | ||
| Q1 25 | 5.0% | 36.6% | ||
| Q4 24 | 65.9% | -154.2% | ||
| Q3 24 | 4.0% | -168.9% | ||
| Q2 24 | 21.8% | -206.2% | ||
| Q1 24 | 27.3% | -358.5% |
资本支出强度BPRNRGNX
| Q4 25 | 4.3% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.0% | 1.2% | ||
| Q4 24 | 7.6% | 5.1% | ||
| Q3 24 | 2.2% | 1.3% | ||
| Q2 24 | 2.1% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率BPRNRGNX
| Q4 25 | 3.54× | — | ||
| Q3 25 | 0.76× | — | ||
| Q2 25 | 4.57× | — | ||
| Q1 25 | 0.23× | 5.53× | ||
| Q4 24 | 2.82× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BPRN
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
